A pharmacokinetic model of TMZ that accounted for the production of DNA adducts and specifically, O6mG, previously applied to GBM patients [23] was linked to a two-stage gene transcription-translation model for MGMT. The gene discussed is MGMT; the disease is glioblastoma.